

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Friday, September 29, 2017 7:49 PM  
**To:** 'Rizwana Sproule'; 'Nadia Agopyan'; 'Alex Babayan'  
**Subject:** BLA 125643 Kite Pharma YESCARTA Risk Evaluation and Mitigation Strategy (REMS) Documents 9.29.17  
**Attachments:** YESCARTA\_REMS\_doc\_20170921\_for OCC--occ redline v2.docx;  
YESCARTA\_REMS\_supp\_redlined\_AMJ\_cz 20170929.docx

Dear Dr. Sproule,

Please see the attached Risk Evaluation and Mitigation Strategy (REMS) Documents for YESCARTA™ (acicabtagene ciloleucel). Please review and if need comment on any revisions you feel should be pointed out to the FDA. Please return the REMS documents back to me by Wed. October 4, 2017, 12:00PM EST. Also, please send a formal amendment to the BLA 125643 as you would the PI. In your return email, let me know if you agree with the recommended changes or you can make revisions with comment. We will continue with this process until we have reached an agreement. Please give me a call if you have question(s) or if you would like to discuss in more detail.

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."